HOME >> BIOLOGY >> NEWS
JCI table of contents: January 2, 2007

EDITOR'S PICK

Genetic mutation alters response to heart failure drugs

The group of drugs known as beta blockers help slow nerve impulses traveling through the heart in order to reduce the heart's workload. This effect is achieved via their action on beta-adrenergic receptors present in cardiac cells. As such, beta blockers have become a mainstay of the treatment regimen for chronic heart failure. However, doctors have remained puzzled by the variable responses to some beta blockers among heart failure patients. In a study appearing in the January issue of the Journal of Clinical Investigation, Stefan Engelhardt and colleagues from the University of Wrzburg, Germany, explain why some heart failure patients may respond better than others to certain beta blockers. The secret lies in a single amino acid change in the beta1-adrenergic receptor, that may differ from person to person, which alters the receptor's conformation and in doing so may alter the receptor's response to a given beta blocker.

Engelhardt and colleagues examined variant beta1-adrenergic receptors in which the amino acid at position 389 had been replaced by either an arginine or a glycine residue. The authors were able to directly assess, in real time, the effects of 3 different beta1-adrenergic receptor antagonists bisoprolol, metoprolol, and carvedilol on the Arg389 and Gly389 variant beta1-adrenergic receptors in rat cardiac cells. They found that while each of these drugs caused a conformational change in the receptors, the effect of bisoprolol and metoprolol was minor and did not noticeably differ between the Arg389 and Gly389 receptor variants. In contrast, carvedilol treatment induced a response from the Arg389 variant that was 2.5-fold that of the Gly389 variant. This was attributed to carvedilol's ability to induce a more extreme conformational change in the Arg389 variant of the receptor, resulting in significantly dampened cAMP signaling in c
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
2-Jan-2007


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents January

(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)... March 10, 2015   Tute Genomics , pioneer ... selected by next-generation sequencing company PrimBio Research Institute ... and targeted gene panel interpretation. PrimBio, a ... the most current technologies to support the work of ... company offers two types of exome sequencing services: 1) ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
(Date:3/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... platform company serving the global pharmaceutical, biotechnology, and ... New Drug (IND) application for WuXi MedImmune,s novel ... accepted for review by the China Food and ... 2012, MedImmune, the global biologics research and development ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... that after dealing with certain matters, including the appointment ... held on March 26, 2015 (the "Meeting") was adjourned, ... 8, 2015 at 11:00 a.m. ( Toronto ... been changed from that previous disclosed. The Meeting will ...
(Date:3/26/2015)... , March 26, 2015 PAREXEL ... global clinical research organization , announced ... definitive agreement to acquire all of the ... a leading provider of specialized pharmacovigilance services, ... the collection, detection, assessment, monitoring, and prevention ...
(Date:3/25/2015)... market is one of the most attractive in the ... plus a growing economy and increasing government investment in ... The Russian market is set to grow at twice ... estimates around 10-15% annually reaching an approximate market value ... Cross Green Cross provides total healthcare solutions ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
Cached News: